Skip to main content
Premium Trial:

Request an Annual Quote

PrecisionLife Acquires Danish Collaborator GenoKey

NEW YORK — PrecisionLife said on Wednesday that it has acquired Danish genomic analytics firm GenoKey.

PrecisionLife said that it has worked with GenoKey, which is now a wholly owned subsidiary, on the development of the technology underlying its flagship artificial intelligence-driven bioinformatics platform for biomarker discovery and drug target validation. 

"The acquisition of GenoKey solidifies a long-term, highly productive collaboration around core IP and positions PrecisionLife for its next round of investment and growth," PrecisionLife CEO Steve Gardner said in a statement.

Following the acquisition, UK-based PrecisionLife said it will keep its core platform development operations at GenoKey's site in Denmark, which it plans to expand with additional hires. GenoKey Cofounder and Chairman Hans-Christian Brahe Møller will join the board of the new subsidiary.

Financial and other terms of the acquisition were not disclosed.